Continuum Advisory’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Continuum Advisory's KYMR Position: Q3 2026 in Review
Continuum Advisory opened a new position in Kymera Therapeutics (KYMR) in Q3 2026: 13 shares worth $1.45K. The stake represents ﹤0.01% of the portfolio and ranks #1748 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in KYMR as recently as Q1 2024.
Continuum Advisory first reported a position in KYMR in Q1 2024 and has held it in 2 quarters since. 299 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Continuum Advisory held 13 shares of Kymera Therapeutics worth $1.45K as of Q3 2026.
- Kymera Therapeutics was a new Continuum Advisory position in Q3 2026.
- Kymera Therapeutics made up ﹤0.01% of Continuum Advisory's portfolio in Q3 2026, its #1748 holding.
- Continuum Advisory first reported a position in Kymera Therapeutics in Q1 2024 and has held it in 2 quarters since.
- 299 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Continuum Advisory's 13F filing for Q3 2026, filed 13 Nov 2026.